Anthropic launches Claude Science

Anthropic has moved beyond selling AI tools to researchers and into planning its own drug-discovery work. The company launched Claude Science on June 30 as a scientific-research workbench built on its existing Claude models, and media reports this week said Anthropic also plans internal studies aimed at neglected diseases. WTOP reported on July 9 that Anthropic created Claude Science to help scientists speed drug development and that the company plans to run studies on overlooked diseases. Anthropic’s own announcement described Claude Science as a customizable app that integrates commonly used research tools and packages, produces auditable artifacts and gives scientists flexible access to compute resources. (anthropic.com) ### So what exactly did Anthropic launch? Claude Science is a beta product for scientific research rather than a separate new foundation model. Anthropic says the app can run analyses, search databases and trace each step from data wrangling to publication, with native support for proteins, structures and molecules. June 30 was the formal launch date in Anthropic’s newsroom, where the company said the product is “now available.” The announcement says the app is designed to reduce the friction of working across tools such as PubMed, Jupyter, R and cluster terminals that researchers typically use in separate environments. (wtop.com) ### Where does the drug-discovery piece come in? CNBC reported on June 30 that Anthropic will start an internal drug-discovery program as part of a broader push to sell AI tools to pharmaceutical companies. (claude.com) Jonah Cool, Anthropic’s head of life sciences partnerships, told CNBC that the company’s goal is to focus on neglected diseases while it builds and sells AI tools for life sciences customers. (anthropic.com) WTOP’s July 9 report tied that internal research effort directly to Claude Science, saying the company plans its own studies for overlooked diseases. Anthropic’s public product materials do not, by themselves, lay out a full pipeline of named disease programs, trial dates or partner laboratories, but outside coverage this week has consistently described an internal research effort alongside the software launch. (cnbc.com) ### What does Anthropic say Claude Science can do for researchers? Anthropic says Claude Science combines literature analysis, data processing and compute management in one environment. The company’s product page says the software traces outputs back to code, a feature aimed at reproducibility, and its launch materials describe the app as customizable for the tools scientists already use. (wtop.com) Earlier Anthropic life-sciences announcements show this launch builds on a longer push into biology and healthcare. In October 2025, the company introduced Claude for Life Sciences, and in January 2026 it said it was expanding healthcare and life-sciences features; in June it also published research on improving Claude’s chemistry capabilities. ### Is Anthropic also trying to seed outside research? (anthropic.com) Anthropic launched an AI for Science program in May 2025 to provide API credits for high-impact research, with a particular focus on biology and life sciences. That program predates Claude Science, but it shows the company had already been trying to place its models inside scientific workflows before this latest product release. Another report this week said Anthropic intends to support up to 50 Claude Science projects with grants of up to $30,000 and that applications are due by July 15, 2026. (anthropic.com) Anthropic’s event page also shows it used a June 30 virtual briefing to present Claude Science alongside life-sciences executives and research institutions. ### What happens next? July 15 is the next dated milestone tied to Claude Science’s outside research push because that is the application deadline cited for Anthropic’s project grants. (anthropic.com) Anthropic has also said Claude Science is available in beta to paid Claude users, while its internal neglected-disease work remains at the program stage described by WTOP and CNBC rather than a publicly detailed clinical timetable. (dataconomy.com)